Amylyx PharmaceuticalsvsJohnson & Johnson

AMLX and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

AMLX

Amylyx Pharmaceuticals, Inc.

$26.62

Value $3.4B

-3.27%
AMLX's page

Amylyx Pharmaceuticals (AMLX) has a market value of $3.4B and Johnson & Johnson (JNJ) $657B. Over the last year, with dividends, AMLX moved +90.4% and JNJ +39.7%. Dividend yield: AMLX none, JNJ 1.94%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMLX$3.4B

    JNJ$657B

    JNJ is 192 times AMLX

  • Revenue, 12 months

    AMLX$0

    JNJ$99.3B

  • Net income, 12 months

    AMLX-$163M

    JNJ$16.1B

  • Operating margin

    AMLX–

    JNJ–

  • ROIC

    AMLX-36.5%

    JNJ12.4%

    48.9 points apart

  • P/E

    AMLX–

    JNJ40.8

  • Dividend yield

    AMLX0.0%

    JNJ1.9%

    1.9 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMLX+120.5%

JNJ+98.2%

0100200300202420252026
Returns by period
PeriodAMLXWith dividendsJNJWith dividends
1 year since November 17, 2025+90.4%Price +90.4%+39.7%Price +36.6%
3 years since November 17, 2023+120.5%+30.2% a yearPrice +120.5%+98.2%+25.6% a yearPrice +82.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMLXAmylyx PharmaceuticalsJNJJohnson & Johnson

Valuation

AMLXJNJ
Valuation
Price$26.62$272.70
Market value$3.4B$657B
Enterprise value (EV)$2.7B$685B
P/E–40.8
P/E, 5-year median–21.9
P/B4.58.1
EV/EBIT–38.6
Free cash flow yield–3.1%

Results and growth

AMLXJNJ
Results and growth
Revenue, 12 months$0$99.3B
Net income, 12 months-$163M$16.1B
Free cash flow, 12 months-$130M$20.6B
Earnings per share, 12 months-$1.42$6.59
Revenue growth, year on year-100.0%6.1%
Revenue growth a year, past–+2.7%over 5 years
EPS growth a year, past–+14.9%over 5 years

Margins and returns on capital

AMLXJNJ
Margins and returns on capital
Gross margin–67.6%
Operating margin––
Net margin–16.2%
ROIC-36.5%12.4%
ROE-42.9%19.7%

Balance sheet

AMLXJNJ
Balance sheet
Cash$768M$17.2B
Total debt$4.9M$44.7B
Net debt / EBITDA–1.1
Interest cover–18.0×

Dividends and buybacks

AMLXJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMLX or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Amylyx Pharmaceuticals or Johnson & Johnson?

By market value, Johnson & Johnson ($657B) is about 192.0 times Amylyx Pharmaceuticals ($3.4B), at today's prices.

How did AMLX and JNJ stock do over the last 3 years?

Since November 17, 2023, AMLX's price moved +120.5% and JNJ's +82.1%. With dividends: AMLX +120.5% (+30.2% a year), JNJ +98.2% (+25.6% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMLX or JNJ?

The dividend yield at today's price is none for Amylyx Pharmaceuticals and 1.94% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

Which is the better investment, Amylyx Pharmaceuticals or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.